Avadomide (CC-122) is primarily used in the field of oncology for the treatment of various hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL) and multiple myeloma. It functions as a cereblon modulator, enhancing the immune system's ability to target and destroy cancer cells. By binding to cereblon, it promotes the degradation of specific transcription factors like Ikaros and Aiolos, which are essential for cancer cell survival, thereby inhibiting tumor growth. Additionally, it has shown potential in combination therapies, improving the efficacy of other anticancer agents. Research is ongoing to explore its applications in other types of cancers and its role in enhancing immune responses in therapeutic settings. As an investigational drug, it is primarily evaluated in clinical trials to assess safety and efficacy.